Literature DB >> 20955108

Evaluation of models for predicting drug-drug interactions due to induction.

Odette A Fahmi1, Sharon L Ripp.   

Abstract

IMPORTANCE OF THE FIELD: Drug-drug interactions caused by induction of metabolizing enzymes, particularly CYP3A, can impact the efficacy and safety of co-administered drugs. It is, therefore, important to understand a new compound's potential for enzyme induction and to understand how to use the induction data generated in vitro to predict potential for drug-drug interactions in vivo. AREAS COVERED IN THIS REVIEW: Recent advances in methods for using in vitro data to predict potential for CYP3A induction in vivo are reviewed. WHAT THE READER WILL GAIN: The reader will gain a comprehensive understanding of the advantages and disadvantages of various prediction methods for induction and be able to directly compare different methods using a common in vitro data set. TAKE HOME MESSAGE: The various methods for predicting clinical CYP3A induction from in vitro induction data all have demonstrated utility; it is the authors' opinion that the correlation-based approaches offer as good or better predictivity and have simpler input requirements than more complex approaches. Of the different correlation approaches, the relatively simple unbound C(max)/EC(50) or AUC/EC(50) approaches are the simplest and yet show the best correlation to the observed clinical data. While the approaches discussed herein represent an improvement in our understanding of the predictive value of in vitro induction data, it is important to recognize that there is still room for improvement in quantitative prediction of magnitude of drug interactions due to induction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20955108     DOI: 10.1517/17425255.2010.516251

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  10 in total

1.  Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).

Authors:  Evan D Kharasch; Pamela Sheffels Bedynek; Christine Hoffer; Alysa Walker; Dale Whittington
Journal:  Anesthesiology       Date:  2012-02       Impact factor: 7.892

2.  Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100.

Authors:  Nellie E Byun; Michael Grannan; Michael Bubser; Robert L Barry; Analisa Thompson; John Rosanelli; Raajaram Gowrishankar; Nathaniel D Kelm; Stephen Damon; Thomas M Bridges; Bruce J Melancon; James C Tarr; John T Brogan; Malcolm J Avison; Ariel Y Deutch; Jürgen Wess; Michael R Wood; Craig W Lindsley; John C Gore; P Jeffrey Conn; Carrie K Jones
Journal:  Neuropsychopharmacology       Date:  2014-01-20       Impact factor: 7.853

3.  Natural Products: Experimental Approaches to Elucidate Disposition Mechanisms and Predict Pharmacokinetic Drug Interactions.

Authors:  Mary F Paine
Journal:  Drug Metab Dispos       Date:  2020-08-13       Impact factor: 3.922

4.  Pharmacological Optimization for Successful Traumatic Brain Injury Drug Development.

Authors:  Samuel M Poloyac; Richard J Bertz; Lee A McDermott; Punit Marathe
Journal:  J Neurotrauma       Date:  2019-04-10       Impact factor: 5.269

5.  A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison.

Authors:  Diansong Zhou; Maria Sunzel; Maria D Ribadeneira; Mark A Smith; Dhaval Desai; Jianrong Lin; Scott W Grimm
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

6.  Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.

Authors:  Pankaj Gupta; Christine Alvey; Rong Wang; Martin E Dowty; Odette A Fahmi; Robert L Walsky; Richard J Riese; Sriram Krishnaswami
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

Review 7.  In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions.

Authors:  Parthena Martin; Maciej Czerwiński; Pallavi B Limaye; Brian W Ogilvie; Steven Smith; Brooks Boyd
Journal:  Pharmacol Res Perspect       Date:  2022-06

8.  Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based Relative Induction Score Approach.

Authors:  Rongjun Zuo; Feng Li; Sweta Parikh; Li Cao; Kirsten L Cooper; Yulong Hong; Jin Liu; Ronald A Faris; Daochuan Li; Hongbing Wang
Journal:  Drug Metab Dispos       Date:  2017-01-06       Impact factor: 3.922

9.  Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir.

Authors:  Helena Rabie; Tjokosela Tikiso; Janice Lee; Lee Fairlie; Renate Strehlau; Raziya Bobat; Afaaf Liberty; Helen McIlleron; Isabelle Andrieux-Meyer; Mark Cotton; Marc Lallemant; Paolo Denti
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

10.  Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications.

Authors:  Tjokosela Tikiso; Helen McIlleron; David Burger; Diana Gibb; Helena Rabie; Janice Lee; Marc Lallemant; Mark F Cotton; Moherndran Archary; Stefanie Hennig; Paolo Denti
Journal:  Br J Clin Pharmacol       Date:  2021-08-12       Impact factor: 3.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.